SBI Securities Co. Ltd. Buys New Shares in Tempus AI, Inc. (NASDAQ:TEM)

SBI Securities Co. Ltd. purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 19,938 shares of the company’s stock, valued at approximately $673,000.

A number of other institutional investors have also recently added to or reduced their stakes in TEM. ARK Investment Management LLC grew its position in Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock valued at $186,343,000 after acquiring an additional 3,141,487 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 166.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after buying an additional 2,021,394 shares during the period. NEA Management Company LLC boosted its position in shares of Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after buying an additional 813,169 shares during the period. Tidal Investments LLC purchased a new stake in shares of Tempus AI in the third quarter worth about $7,633,000. Finally, abrdn plc purchased a new stake in shares of Tempus AI in the fourth quarter worth about $2,784,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

NASDAQ:TEM opened at $50.93 on Tuesday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The business’s 50-day simple moving average is $52.70 and its 200 day simple moving average is $52.52.

Analyst Ratings Changes

TEM has been the subject of several analyst reports. TD Cowen reaffirmed a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Bank of America upped their target price on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Finally, Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.09.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now owns 246,085 shares in the company, valued at $10,431,543.15. This represents a 17.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now owns 27,894 shares in the company, valued at $1,166,248.14. The trade was a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,823,701 shares of company stock worth $320,906,059 over the last quarter.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.